Fluent BioSciences Inc.

Website https://www.fluentbio.com

Founded 2018

Employees 3

Follow

Overview

In the past few years with projects such as the Human Cell Atlas, medical research has embarked on a massive journey to understand how the trillions of human cells function. This infant field, however, only has limited, complex and inflexible commercial tools. Fluent BioSciences’ unique instrument-free self-assembling technology provides game-changing flexibility to single cell expression as well as ultra-high sensitivity molecular assays.

Management Team

Founder, President, CEO, and Board of Directors

Sepehr Kiani

Ph.D. MIT Over 22 years experience in both building start-up businesses (+$100M exit and IPO) and large mature enterprises. A hands-on leader with broad technical, operational, market and business knowledge, and the flexibility to traverse from strategic to tactical requirements. 35+ issued and actively pending patents in semiconductor equipment, optics, fluids handling, microfluidics, molecular biology, and sequencing.

Founder, Adviser, and Board of Directors

Adam Abate

Ph.D. University of Pennsylvania, postdoc Harvard Physicist and Assoc. Professor of Bioengineering and Therapeutic Sciences at UCSF. Adam is a world-renowned researcher in the area of high-throughput biological assays. Several companies founded on his cutting-edge microfluidics. He has over 20 patents, a hundred publications, and is an investigator for the Chan Zuckerberg Biohub and California Institute for Quantitative Biosciences.

Founder, Adviser, and Board of Directors

Bill Hyun

MS George Washington Univ, Ph.D. University Debrecen Director, Lab for Advanced Cytometry Department of Lab Medicine at UCSF. Bill is a respected expert in both research and clinical technology development with a strong concentration on developing commercially successful cytometric and genomic instrumentation and applications. Bill has published over 100 peer-reviewed publications.

Founder and Adviser

Gary Zweiger

Ph.D. Stanford U., School of Medicine, Genetics Dept. Gary brings his vast bus. dev. experience in DNA sequencing and other genomics technologies (microarrays, PCR, imaging, etc) to Fluent. He has worked in BD at Affymetrix, Life Technologies and Agilent. Now as investor/entrepreneur, he helps startups evaluate markets, partnering and investor interest in liquid biopsy assays and tools, sequencing, sample prep, genome editing, and therapeutics.

Science Adviser

Tony Godfrey

Ph.D. Brunel University, postdoc UCSF Professor of Surgery, Computational Biomedicine and the Asso. Chair for Research in the Department of Surgery at BU School of Medicine. Dr. Godfrey’s research is in cancer biomarkers and molecular pathology for clinical application of novel genomic technologies. He is a standing member of the NCI Cancer Biomarkers Section. He has published 72 peer-reviewed articles, 4 book chapters and has 4 issued patents.

Director of Research and Development

Robert Meltzer

Ph.D. Baylor College of Medicine, postdoc University of Alabama, Birmingham Robert brings over a decade of experience in developing advanced genomic analysis technologies for applications in infectious disease, food safety, and cancer diagnostics. He leverages his background in Biomedical Engineering and Molecular Biophysics to innovate novel technologies integrating fluorescence detection, microfluidic systems, and sound molecular biochemistry.

Molecular Biology

Desiree Schenk

Ph.D. Purdue University Desiree studied the effects of nanomedicine for therapeutic delivery for her doctoral work in Biomedical Engineering. Post graduation, she joined a startup in its early stages that develops targeted NGS panels, specifically for oncology, with a focus on clinical utility and implementation; working on multiple aspects of the assay design life-cycle including target selection, early commercialization and customer interaction

Director of Molecular Biology

Kristina Fontanez

Ph.D. Harvard University, postdoc MIT Kristina has a multidisciplinary background in molecular biology and microbiology, which she leveraged to develop commercial life science and genomics products including a DNA sequencing platform and multiplex PCR assays for a droplet microfluidics platform. She has cultivated a deep expertise in biostatistics, bioinformatics, and the product development process including agile development principles.